Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Anadrol and Minoxidil Interaction: Monitor | Peptide Database

Compound Profiles Anadrol Oral Anabolic Steroid | Extreme Mass & Strength Oxymetholone exerts its effects primarily through binding to the androgen receptor (AR) to promote protein synthesis and nitrogen retention in skeletal muscle. As a DHT derivative, it ca

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Compound Profiles

Anadrol

Oral Anabolic Steroid | Extreme Mass & Strength

Oxymetholone exerts its effects primarily through binding to the androgen receptor (AR) to promote protein synthesis and nitrogen retention in skeletal muscle. As a DHT derivative, it cannot be converted to estrogen by the aromatase enzyme.

Minoxidil

Vasodilator | Hair Growth Stimulation

Minoxidil is a potassium channel opener that acts on ATP-sensitive potassium channels in vascular smooth muscle cells, causing vasodilation. When applied topically or taken orally, it is converted to its active metabolite minoxidil sulfate by the enzyme sulfotransferase (SULT1A1) in hair follicle outer root sheath cells.

Combined Organ Load

Shared Safety Flags

Frequently Asked Questions

Can I take Anadrol with Minoxidil?

Yes, but with caution. Both Anadrol and Minoxidil can raise blood pressure. Monitor BP regularly and consider adding cardiovascular support (cardarine, telmisartan, or similar). Regular monitoring is advised.

Is Anadrol and Minoxidil safe together?

Based on pharmacological analysis, this combination is considered monitor. However, shared safety flags include: blood pressure raising, teratogenic. Monitor accordingly.

What are the interactions between Anadrol and Minoxidil?

Both Anadrol and Minoxidil can raise blood pressure. Monitor BP regularly and consider adding cardiovascular support (cardarine, telmisartan, or similar). This assessment has 60% confidence and is inferred from pharmacological mechanism analysis.

How should I time Anadrol and Minoxidil?

Anadrol has a half-life of ~8-9 hours and Minoxidil has a half-life of ~4 hours (oral); topical effects persist significantly longer due to local tissue retention. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

What's the addiction risk of phenibut vs benzodiazepines?

Phenibut carries similar addiction and withdrawal risk to benzodiazepines despite not being a benzo. Physical dependence can develop in as little as 1-2 weeks of daily use, and withdrawal i…

Source: peptide-db.com
comparison

What's the dose range for cognitive enhancement versus being too much?

The cognitive 'sweet spot' is 0.5-2 mg/kg body weight (roughly 35-140 mg for a 70 kg person). Doses above 2 mg/kg often shift from antioxidant to pro-oxidant effects, becoming counterproduc…

Source: peptide-db.com
comparison

What's the ideal 5/5 vs 10/3 ratio for Tesa/IPA and when to use each?

5/5 (equal parts) provides balanced GH stimulation suitable for general recovery. The 10/3 (higher tesamorelin) variant emphasizes visceral fat loss and metabolic effects. Choose 5/5 for at…

Source: peptide-db.com
Research context

Read sources and limitations before applying a claim.

Research Indications

Originally FDA-approved for testosterone replacement in hypogonadal men. Fluoxymesterone was used to treat delayed puberty and androgen deficiency, though it has been almost entirely replaced by injectable testosterone and transdermal preparations due to its hepatotoxicity and unfavorable side effect profile. FDA-approved for palliative treatment of androgen-responsive, advanced inoperable breast cancer in women, typically 1-5 years post-menopause. This indication is rarely used today due to the availability of aromatase inhibitors and targeted therapies with superior safety profiles. Used by powerlifters and strength athletes in the final 2-4 weeks before a competition to maximize strength output, aggression, and neural drive without adding bodyweight or water retention. The compound's effects on the central nervous system produce a pronounced increase in competitive intensity. Employed by competitive bodybuilders in the last 2-4 weeks before stage to enhance muscle hardness, vascularity, and visual density without water retention. The non-aromatizing nature ensures no subcutaneous water accumulation during the critical final phase of contest preparation. Historically used by fighters and combat sport athletes to increase aggression and power output while staying within a weight class, as it adds no water weight. This use carries significant ethical and regulatory concerns given anti-doping testing.

Source: peptide-db.com ↗

Research Indications

PNC-27 shows selective cytotoxicity against pancreatic cancer cells in research. Demonstrated effectiveness against breast cancer cell lines. Induces necrosis of K-562 leukemia cells through HDM-2 binding. Shows selective targeting of melanoma cells. Most effective against cancers with high membrane HDM-2 expression. Model compound for studying cancer-selective therapies.

Source: peptide-db.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

Dosing Protocols

Currently in experimental stages. The original 2017 mouse study used 5 mg/kg intraperitoneally, three times on alternate days. For a 60kg human, this translates to approximately 25 mg per dose. Self-experimenters have reported using subcutaneous injection. Storage at -20°C required due to peptide stability concerns. Standard senolytic protocol 25-33 mg 3 doses, every other day (6 days total) SubQ or IV Mouse study equivalent 5 mg/kg (translates to ~25 mg for 60kg human) 3 doses on alternate days IP (original study)

Source: peptide-db.com ↗
Side effects

Common Side Effects

Joint pain, stiffness, or dryness (from reduced estrogen-mediated joint lubrication) Hot flashes or flushing Fatigue and general malaise Mood changes (flat affect, irritability, or low mood) Decreased libido (when estrogen is suppressed too aggressively) Headache

Source: peptide-db.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →